Stocks · News reference

Eli Lilly Says Retatrutide Shows Cardiovascular, Diabetic Benefits

Jul 23, 2026, 1:00 PMVandana Singh

Eli Lilly reports positive Phase 3 data for retatrutide, showing major weight loss in adults. US regulatory submission is planned for 2027.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 7:30 PMVandana Singh
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
Read original at benzinga
LLY
BenzingaAug 26, 2026, 6:40 PMEvette Mitkov
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week
Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.
Read original at benzinga
LLY
BenzingaAug 26, 2026, 5:04 PMBenzinga Newsdesk
Eli Lilly shares are trading lower. The company reported a real‑world study showing Zepbound cut healthcare costs in adults over 55 with obesity, driven by fewer hospitalizations and ER visits.
Read original at benzinga
LLY
BenzingaAug 26, 2026, 4:58 PMPiero Cingari
Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today
Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.
Read original at benzinga
ANET AU BBWI BSX BTCUSD